Nanjing Pharmaceutical CoSHSE:600713 -0.20%59 EBITDA Margin % is 2.50% as of Mar. 2026, which is 17% below its 10-year median of 3.02. GuruFocus rates SHSE:600713 with a GF Score™ of 59/100 and a GF Value™ of ¥4.50 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 953 Drug Manufacturers companies, Nanjing Pharmaceutical Co ranks worse than 72.72% on this metric.
Nanjing Pharmaceutical Co (SHSE:600713) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nanjing Pharmaceutical Co EBITDA Margin % Related Terms
Nanjing Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600713 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Nanjing Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanjing Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nanjing Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Pharmaceutical Co (SHSE:600713) has a EBITDA Margin % of 2.50% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanjing Pharmaceutical Co and its competitors. This is 17% below median its historical median of 3.02. Over the past decade, Nanjing Pharmaceutical Co's EBITDA Margin % has ranged from 2.38 to 3.37. According to the industry distribution chart, Nanjing Pharmaceutical Co ranks #693 out of 953 companies in the Drug Manufacturers industry, placing it in the top 72.7%.
Is Nanjing Pharmaceutical Co's EBITDA Margin % too high?
Nanjing Pharmaceutical Co's current EBITDA Margin % of 2.50% is 17% below median its 10-year median of 3.02. Over the past 10 years, this metric has ranged from a low of 2.38 to a high of 3.37. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Nanjing Pharmaceutical Co's value of 2.50% is 80.1% below this industry median. Based on the distribution chart, Nanjing Pharmaceutical Co ranks #693 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Nanjing Pharmaceutical Co has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Pharmaceutical Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Nanjing Pharmaceutical Co ranks #693 out of 953 companies for EBITDA Margin %. This places Nanjing Pharmaceutical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.54. Nanjing Pharmaceutical Co's value of 2.50% is 80.1% below this benchmark. Historically, Nanjing Pharmaceutical Co's own EBITDA Margin % has ranged from 2.38 to 3.37 over the past decade. While the company's 10-year median is 3.02 vs. the industry median of 12.54, Nanjing Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Pharmaceutical Co's current EBITDA Margin % of 2.50% is 80.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanjing Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Pharmaceutical Co's current EBITDA Margin % is 2.50%, which is 17% below median its own 10-year median of 3.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Pharmaceutical Co (SHSE:600713) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.50, compared to a current price of ¥5.06 — trading 12.4% above its estimated fair value. The current EBITDA Margin % is 2.50%, which is 17% below median its 10-year median of 3.02 and 80.1% below the Drug Manufacturers industry median of 12.54. Nanjing Pharmaceutical Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nanjing Pharmaceutical Co (SHSE:600713), the current EBITDA Margin % is 2.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Pharmaceutical Co (SHSE:600713) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥5.06 is trading 12.4% above its estimated GF Value™ of ¥4.50.
GuruFocus considers Nanjing Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600713:
EBITDA Margin %: 2.50% (17% below median its 10-year median of 3.02)
GF Value™: ¥4.50 vs. price of ¥5.06 (12.4% above fair value)
Industry Position: 80.1% below the Drug Manufacturers median (#693 of 953)
No single metric tells the full story. See the SHSE:600713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600713 has been successfully added to your 
